SCHEMBL3487281

SCHEMBL3487281

Cc1cc(Oc2ccc([N+](=O)[O-])c(CNC(=O)O)c2)ccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.43
SLC6A4 P31645 1/20 0.43
KCNH2 Q12809 1/20 0.43
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
PPARG P37231 2/20 0.41
PPARD Q03181 2/20 0.41
PPARA Q07869 2/20 0.41
ALDH1A1 P00352 5/20 0.40
MAPT P10636 2/20 0.40
POLB P06746 1/20 0.40
KDM4E B2RXH2 2/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
MAPK1 P28482 1/20 0.39
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3487273 1.00 HTR2A (0.43) HTR2ASLC6A4KCNH2MEN1KMT2A
SCHEMBL3487468 0.91 MEN1 (0.42) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3487476 0.91 MEN1 (0.42) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3489426 0.91 MAPT (0.47) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3489430 0.91 MAPT (0.47) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3488697 0.89 KMT2A (0.44) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3488700 0.89 KMT2A (0.44) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3487910 0.87 HSPB1 (0.46) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3487917 0.87 HSPB1 (0.46) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3488903 0.86 SIRT5 (0.43) MEN1KMT2ASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA HTR2A 1485/4885SLC6A4 1449/4885KCNH2 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.